BCM
PSTX

Bayesian Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Bayesian Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,200
Closed -$32.5K – 1164
2024
Q1 		$32.5K Buy
+10,200
New +$34K ﹤0.01% 742

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Bayesian Capital Management's PSTX Position: Q2 2024 in Review

Bayesian Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2024, closing a stake of 10,200 shares — an estimated $32.5K sold.

Bayesian Capital Management first reported a position in PSTX in Q1 2024 and held it in 1 quarter. The position peaked at $32.5K in Q1 2024. 93 funds tracked by Wall St. Rank hold PSTX as of Q2 2024.

  • Bayesian Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 10,200 Poseida Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $32.5K.
  • Bayesian Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Bayesian Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $32.5K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.